Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2026)
Lyell Immunopharma recorded quarterly Return on Capital Employed of 83.11% in Q1 2026, little changed quarter-over-quarter from 83.0% in Q4 2025, and up 293.0% year-over-year from 21.15% in Q1 2025.
Lyell Immunopharma's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 83.11% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 293.0% year-over-year to 83.11%; the TTM figure through Mar 2026 stood at 83.11% (up 293.0% YoY), while the FY2025 annual figure was 73.6%, down 1029.0% from the prior year.
- Return on Capital Employed came in at 83.11% for Q1 2026 at Lyell Immunopharma, roughly flat from 83.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.32% in Q2 2022 to a low of 96.07% in Q2 2025.
- A 5-year average of 47.68% and a median of 34.8% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 6099 bps in 2025 and jumped 293 bps in 2026, its largest moves.
- Lyell Immunopharma's Return on Capital Employed stood at 20.32% in 2022, then tumbled by 65 bps to 33.47% in 2023, then slumped by 114 bps to 71.57% in 2024, then dropped by 16 bps to 83.0% in 2025, then slipped by 0 bps to 83.11% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 83.11%, 83.0%, and 93.99% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | -83.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.11% |
| Dec 31, 2025 | -83.00% |
| Sep 30, 2025 | -93.99% |
| Jun 30, 2025 | -96.07% |
| Mar 31, 2025 | -86.04% |
| Dec 31, 2024 | -71.57% |
| Sep 30, 2024 | -36.00% |
| Jun 30, 2024 | -35.08% |
| Mar 31, 2024 | -34.80% |
| Dec 31, 2023 | -33.47% |
| Sep 30, 2023 | -25.93% |
| Jun 30, 2023 | -25.46% |
| Mar 31, 2023 | -20.61% |
| Dec 31, 2022 | -20.32% |
| Sep 30, 2022 | -23.18% |
| Jun 30, 2022 | -20.32% |
| Mar 31, 2022 | -21.53% |
| Dec 31, 2021 | -19.24% |
| Sep 30, 2021 | -17.90% |